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At present there is relatively little information concerning the type-specific 
aspects of immunity to group A streptococcal infections in man.  It has been 
demonstrated that an individual may suffer several different group A strepto- 
coccal infections within a  single year.  Although relatively few patients have 
been followed over long periods of time with adequate bacteriological studies, 
we do not know of a single instance in which it has been shown that the same 
patient suffered more than one nasopharyngeal infection with the same type of 
streptococcus.  It is also now well known that the great majority of late puru- 
lent  complications  (1-5),  and  invariably  the  relapses  and  intercurrent  sore 
throats (1-3, 6) occurring in patients with scarlet fever, are due to streptococci 
of a  different type from that  which  caused  the patient's  original scarlatinal 
infection. 
On the other hand, it is generally believed, although direct proof is usually 
lacking, that patients may suffer autogenous reinfections of other parts of the 
body with the same types of streptococci they are carrying in their respiratory 
tracts.  Puerperal sepsis (7-10), wound infections (11), erysipelas (12-14), and 
paronychia (15) are examples of such reinfections.  Some of these individuals, 
however, may have been healthy carriers; but in many instances they undoubt- 
edly had previously suffered nasopharyngeal infections with these same types; 
particularly is this true in facial erysipelas where commonly there is a history of 
preceding sore throat or upper respiratory tract infection. 
Practically all laboratory experiments dealing with immunity to and protec- 
tion against group A streptococci have been done with small animals, usually 
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mice, which are unnatural hosts for this group of microorganisms; and highly 
artificial measures have been used to induce infections.  From these experi- 
ments, however, it has been conclusively demonstrated that both passive and 
active immunity are type-specific; that is, the immunity is correlated with the 
antibody directed toward the type-specific M  protein (16-18). 
In contrast to the smaller laboratory animals, it is known that monkeys may 
harbor group A  streptococci in their nasopharynges (19, 20) and occasionally 
may suffer spontaneous infections (21) with this group of microorganisms.  In 
this respect monkeys appear to approximate man in their host relationship with 
respect to group A  streptococci; hence, it seems probable that a  study of im- 
munity to nasopharyngeal infections in monkeys might shed more light on the 
same problem in human beings.  The following report deals with such obser- 
vations. 
Methods of Study 
Thirteen young male and female Macaca mulalta weighing between 2180 and 3720 gm. were 
used.  All were healthy with negative tuberculin tests and normal chest x-rays at the begin- 
ning of the study, and all remained well while under observation.  The monkeys were housed 
singly or in pairs in small cages in two well ventilated rooms.  Only animals inoculated with 
the same strain of streptococci were put in cages together.  No cross or spontaneous strepto- 
coccal infections were observed. 
Twelve different strains of group A streptococci representing 6 different types of varying 
antigenic composition were employed for the inoculations.  Four strains (1RS85, 5RS101, 
11RS50, and 1RSC150) had been recently isolated from patients with nasopharyngeal infec- 
tions which preceded attacks of rheumatic fever.  The remaining 8, chosen because of their 
known antigenic composition, were from stock cultures which had been preserved in the dried 
state.  The type, antigenic composition, and source of each strain are given in Table I. 
Eighteen hour cultures grown in modified  Todd-Hewitt broth (23) and resuspended in equal 
volumes of saline were used for inoculation.  One and a half cc. of the freshly prepared saline 
suspension was dropped into each nostril of a monkey under deep ether  anesthesia.  The 
inocula contained between 70 and 450 million microorganisms  per co. 
The following  data were collected from all of the animals at weekly intervals for at least 8 
weeks following each inoculation: nose and throat cultures made in duplicate on rabbit and 
sheep blood agar plates; leucocyte counts; erythrocyte sedimentation rates; antifibrinolysin 
and antistreptolysin  O determinations.  On the sera from a limited number of animals ag- 
glufinin and bacteriostatic tests also were made.  The blood agar plates were incubated for 
18 hours at 37°C.; and representative colonies of all hemolytic streptococci were then picked 
to broth for grouping and typing according to the method of Lancefield (24) and Swift, Wilson, 
and Lancefield (25).  Antistreptolysin O determinations were made according to the method 
of Todd  (26) and modified as previously described (27); the antifibrinolysin determinations 
were made according to the method described by Tillett, Edwards, and Garner (28) and Bois- 
vert (29).  The Westergren method (30), with tubes 1.5 by 200 ram., was used to determine 
the erythrocyte sedimentation rate. 
The agglutinin tests were done according to the technique described by Lancefield (18). 
Bacterial suspensions were prepared from cultures grown in modified Todd-Hewitt broth at 
room temperature  for 12 to 18 hours.  The bacteria were separated by centrifugation  and 
resuspended in the desired concentration in fresh broth.  These suspensions were added in 
volumes of 0.5 cc. to equal volumes of progressive twofold serum dilutions in broth.  Readings ROBERT  F.  WATSON~ SIDNEY  ROTHBARD,  AND  HOMER  F.  SWIFT  129 
TABLE I 
The  Type,  Antigenic  Composition, and  Source of Strains  of Group A  Streptococci Used for 
I~wcu2ations 
Strain 
1RS85 
5RS101 
C51 
J17F 
11RS50 
24RS50G§ 
T12G 
T12/36/0 
E14/R31-27/ON 
C630 
$23/97/1 
1RSCIS0 
_  rype  ,  Antigenic 
composition 
M  T 
32  32  32 
32  32  32 
26  26  26 
26  26  05 
26  0  0~ 
12  0  12 
12  12  12 
12  12  10 
14  14  0 
14  14  14 
17  17  17 
Source 
Acute pharyngitis followed by rheumatic fever, 
Rockefeller Hospital 
Acute pharyngitis followed by rheumatic fever, 
Rockefeller Hospital 
Dr. Ann Kuttner,  Irvington House, New York 
Rheumatic fever, strain R17, Dr. A. F. Cobum 
Acute pharyngitis followed by rheumatic fever, 
Rockefeller Hospital 
Recovered from same patient as strain llRS50, 
4½ months later 
Scarlet fever, strain S.F.42, Dr. F. Griifith 
Strain T12G passed through 36 mice 
Scarlet  fever,  strain  NYS,  Dr.  A.  R.  Dochez, 
after rabbit and mouse passage 
Uncertain 
Pneumonia, Rockefeller Hospital, after 97 mouse 
passages 
Scarlet  fever  followed  by  rheumatic  fever, 
Rockefeller Hospital 
* NC =  not classified. 
~: Strains  11RS50  and 24RS50G contain a  common agglutinogen which is neither the M 
or T  antigen.  11RS50  was obtained from a patient with acute pharyngitis followed by an 
attack of rheumatic fever.  24RS$0G was isolated from same patient 4~ months later during 
convalescence from attack of rheumatic fever.  Strain 24RSSOG recovered the capacity to 
produce the M  antigen which proved to be type 26 following serial mouse passage. 
§ G indicates glossy,  avirulent variant. 
li Previously this strain, which was derived from strain NY5 by animal passage, has been 
classified as type  10.  Recently (22)  it has been demonstrated  that  the M  antigen of this 
strain is identical serologically with that of Griflith's original type 12 strain, S.F.42, although 
the two strains contain different T  antigens.  Since the M  and not the T  antigen is related 
to  virulence and immunity, it has been customary in  this laboratory to classify types ac- 
cording to the M  antigen; therefore, strain E14/R31-27/O  has been classified  as type 12 to 
conform with the other types. 
were made after incubation for 4 to 6 hours at 56°C.  Controls consisted of at least one pre- 
inoculation monkey serum, aPlain broth control for the suspension,  and a positive control of 
absorbed rabbit antisera of known antibody content.  Suspensions of type 1 streptococd pre- 130  GROUP  A  HEMOLYTIC  STREPTOCOCCI 
viously digested with trypsin were usually used to detect the presence of non-type-specific 
agglutinins. 
The details  of the method for  the bactcriostatic  test  have been previously described (31). 
In  the  present  study  both  the  direct  and  indirect  techniques were  used.  In  the  direct  method, 
0.25 cc.  of fresh  heparinizcd monkey blood was mixed with 0.05 cc. of tenfold  serial  culture 
dilutions  varying  from  10  -8  through I0  -s  respectively  in  each  of  a  series  of  tubes  (7)< 100  ram.); 
in the  indirect  method, each tube contained 0.25 cc.  of  fresh  hepafinizcd blood from afebrile 
children  13  to  9 years  of  age,  0.05  cc.  of  culture  dilution,  and  0.05  cc.  of  the  monkey serum to  be 
tested.  The tubes were sealed  with rubber stoppers and rotated in a mixing machine for  3 
hours.  At  the  end  of  this  time  a  sample  of  the  mixture  was  removed  with  a loop  3.0  ram.  across 
and streaked evenly  over  a quadrant of  a fresh  5 per  cent rabbit  blood agar  plate,  which was 
then incubated for 18 to 24 hours at 37°C.  Growth was recorded as previously described 
(31).  Controls for  the presence of bacteriostatic  antibodies  in  the  human blood,  a preinocu- 
lation  monkey serum, and 2  heterologous type  strains  for specificity  were invariably included. 
The test  was  considered positive  only  if  there  was at  least  a twofold difference  s  in  the  growth 
from  at  least  2 dilutions  as  compared with  the  control. 
Early in the course of  this  study it  became apparent that  following  intranasal  inoculation 
the monkeys showed no obvious clinical  signs  of illness,  nor were their  rectal  temperatures, 
leucocyte counts,  erythrocyte sedimentation rates,  or  body weights  indicative  of  an infection. 
It was noted, however, that following intranasal  inoculation with a matt  (M-containing) 
strain,  the  same strain  could  usually  be  recovered on  nasopharyngeal cultures  for  several  weeks 
following  the  inoculation  and the  antistrcptolysin  O content of  the  scra  of  these  animals gen- 
erally  showed a significant  increase  in  titre.  Furthermore, those  monkeys with  negative anti- 
fibrinolysin  tests  prior  to  successful  implantation usually showed increased  resistance  to  lysis 
of  their  plasma clots  2 to  4 weeks following  the successful  inoculation.  These 3 tests,  there- 
fore,  indicated that the monkcy's nasopharynx not only offered  a favorable medium for the 
implantation but  also  for  the  multiplication  of  group A streptococci. 
In this  study  implantation was considered to  have been successful  if  following  the inocula- 
tion  the  same strain  could be  recovered in  nasopharyngeal cultures  for  at  least  I  week, and/or 
if  the serum antistreptolysin  O  titre  showed a significant  increase.  An increase  in the anti- 
streptolysin  O titre  was considered significant  only  if  the  titre  following  inoculation  increased 
by 2 dilutions  or  more.  Animals were considered to  have had a de~_ite increase  in  the  anti- 
fibrinolysin  content of  their  blood  only  if  there  was  an  increase  of  at  least  two degrees  of  resist- 
ance to  lysis  of  their  plasma clots  following  inoculation. 
EXPERIMENTAL  RESULTS 
In Table II all  of the inoculations made  on each of the 13 monkeys  arc tabu- 
lated in chronological  order  together  with  the results of the nasopharyngeal 
cultures, antistreptolysin O  and antifibrinolysin tests following each inoculation. 
In this table, as well as in subsequent  tables, the results of the nasopharyngeal 
cultures are recorded as positive if the same  strain was recovered  on culture of 
the nose or throat for I week  or longer following inoculation.  Where  the cul- 
l  The authors wish to  acknowledge the  courtesy of  Dr. S.  Z.  Levine of  the  New York Hos- 
pital  and Dr. A. De Forest Smith of the New York Orthopedic Hospital and their respective 
staffs for permission to obtain this blood. 
s Growth on the blood agar plates was  graded from 0  (no growth)  to  q--b-b~  (heavy 
growth).  The test was considered positive then only if there was at least a  ~-b difference in 
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tures are reported as positive, the number of weeks that the inoculating strain 
could be recovered from the nasopharynx is also recorded. 
It is apparent from Table II that the duration of the carrier state varied 
between 9 days (5th inoculation, monkey 13)  and 28 weeks  (lst inoculation, 
monkey 15), and that it was 5 weeks or more with only three exceptions.  Where 
the results of the culture are recorded as negative, it was usually impossible to 
recover the same strain for more than 24  to 48  hours  after inoculation.  In 
other words, it appears that the animal either harbored the  streptococci for 
several weeks to several months, or rapidly removed them from the  site of the 
inoculation. 
The antistreptolysin O titre before and the maximal titre reached after each 
inoculation are also recorded in Table II.  The results of these tests show that 
in 31 or 83.8 per cent of the 37 instances in which the nasopharyngeal cultures 
were positive for at least 1 week following inoculation, there was also a signifi- 
cant increase in the antistreptolysin O  titre.  These results correspond  with 
those found in human beings following proven group A  streptococcal upper 
respiratory tract infections (32, 33).  It is also noteworthy that 4 out of the 6 
failures to obtain a significant increase in the antistreptolysin O titre following 
a positive inoculation occurred after nasal instillation of the same strain, namely 
1RS85.  It is possible that this strain does not produce as much streptolysin O 
as  the  other  strains employed.  Another failure followed the  instillation of 
strain J17F, type 26,  which was used to test the resistance of monkey 36-88 
following a positive inoculation with another type 26 strain, llRS50.  In this 
case, strain J17F was recovered from the animal's nasopharynx for only 10 days 
following inoculation. 
In general the antistreptolysin O  curves following successful implantation 
were similar to those seen following uncomplicated group A streptococcal throat 
infections in man.  The maximal titres occurred between the  2nd and  10th 
weeks following inoculation with the large majority reaching a  maximum be- 
tween the 3rd and 4th weeks.  The highest titre observed was 1,000 units/cc. 
following inoculation of monkey 4-73 with  strain  T12/36/O; the preinocula- 
tion titre in this instance was 150 units/cc. 
The antifibrinolysin tests recorded in Table II did not, in general, prove as 
useful in distinguishing between successful and unsuccessful implantations as 
the antistreptolysin O test for the following two reasons:  First, because the test 
is not quantitative, and further increases in the resistance of plasma clots, which 
showed -4-+ +  to +  + +  +  resistance to lysis before inoculation cottld not be 
measured; second, plasmas from the same animal in some instances showed 
great variation in resistance to lysis from day to day.  s  Such variations make it 
s It may be significant that the antifibrinolysin test showed marked variability (from nega- 
tive to ++++)  in all 4 instances following inoculation with glossy strains.  This marked 
variability was also noted in 2 animals following inoculation with matt strains. 132  GROUP  A  HEMOLYTIC  STREPTOCOCCI 
TABLE  II 
Record of Inoculations  and  Their Resulls 
Monkey 
No. 
Date 
10-14-42 
4-15-43 
9-23-43 
9  11-18-43 
2-25--44 
5-6-44 
10-14-42 
4-15-43 
9-23-43 
11  11-18-43 
2-25-44 
5-6-44 
10-15--42 
2-11--43 
4-8--43 
13  9-23--43 
11-18-43 
2-23-44 
5--3-44 
11-14-42 
9-16-43 
14  12- 2-43 
2-25--44 
5-6--44 
11-14--42 
9-16--43 
15  12-  2-43 
2-25-44 
5-6-44 
10-15-42 
2-11-43 
4-8-43 
36-88  11-16--43 
2-23--44 
5-3--44 
Inoculation  Findings on  Antistrepto-  Antifibrinolysln 
culture  lysln titre  test 
Bdore  Alters  Before  ]  Alters  Strain  Type  Result ]  No. of  weeks* 
1RS85  NC§  +  10 
1RS85  NC  -- 
24RSS0G[I  26  -- 
11RS50  26  +  9 
$23/97/1  14  +  16 
1RS85  NC  -- 
1RS85  NC  +  12 
1RS85  NC  -- 
24RS50G  26  -- 
11RS50  26  +  8 
823/97/1  14  +  6 
1R885  NC  -- 
5RS101  32  +  10 
5RS101  32  -- 
llRSS0  26  +  7 
T12G  12  -- 
T12/36/0  12  +  9 days 
E14/R31-27/0  12  -- 
5R8101  32  -- 
5RS101  32  +  5 
C51  32  +  5 
C630  14  -- 
$23/97/1  14  +  7 
1RS85  NC  +  6 
100  150  -  I  _ 
50  75  -  I  - 
25  50  Variable 
50  250  -  !++++ 
100  2OO  ++++[++++ 
100  150  ++++  ++++ 
25  200  --  ++++ 
25  50  --  ]  + 
25  25  Variable 
25  400  --  ++++ 
250  600  ++++  ++++ 
300  250  ++++  ++++ 
25  4OO  -  [++++ 
75  50  -  -- 
50  250  -  ++++ 
100  100  Variable 
100  400  ++++T++++ 
150  150  ++++,++++ 
100  100  ++  ]  +++ 
100  4OO  ++++  ++++ 
t00  200  ++++  ++++ 
200  250  ++++  ++++ 
200  500  ++++  ++++ 
4OO  4OO  ++++]++++ 
5RS101  32  +  28 
C51  32  -- 
C630  14  +  6 
$23/97/1  14  -- 
1RS85  NC  +  8 
25  100  _  !++++ 
25  25  Variable 
25  100  ++++'++++ 
50  50  ++++~++++ 
50  75  ++++!++++ 
5RS101  32  +  10  75  200  --  [++++ 
5RS101  32  --  100  75  ++++  ++++ 
11RS50  26  +  6  50  100  ++++  ++++ 
J17F  26  +  10 days  50  75  ++++  ++++ 
E14/R31-27/O  12  +  2  50  150  ++++  ++++ 
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TABLE  II---Comluded 
Inoculation 
Monkey 
No. 
Date  Strain  Type 
36-89 
4-75 
1&15-42 
~1143 
4-  843 
11-16-43 
5-  3-~ 
2-2-~ 
5-  1-42 
1~14-~ 
~1143 
Findings on  Antistrepto-  Antifibrinolysin 
culture  ]ysin tltre  test 
4-  8--43 
5-6-44 
2-  242 
5-  1-42 
10--14-42 
2-I 1-43 
4-73  4-  8-43 
9-23--43 
16 
17 
18 
19 
11-1843 
2-23-44 
5-6-44 
11-16--43 
5-23--44 
11--30-43 
5-23-44 
11-3043 
5-23--44 
11-16-43 
2-2344 
5-344 
Result  No. of 
weeks* 
5RS101  32  +  17 
5RSI01  32  - 
11RS50  26  +  8 
J17F  26  - 
5RS101  32  - 
1RS85  NC  +  14 
llRSS0  26  +  9 
1RS85  NC  -- 
11RS50  26  -- 
5RS101  32  +  27 
1RS85  NC  +  8 
1RS85  NC  +  11 
llRS50  26  +  6 
1RS85  NC  -- 
11RS50  26  -- 
5RS101  32  +  10 
T12G  12  -- 
.T12/36/0  12  +  5 
E14/R31-27/0  12  -- 
IRS85  NC  -- 
J17F  26  +  16 
1RSC150  17  -- 
C51  32  +  9 
1RSC150  17  +  6 
C51  32  +  12 
1RSC150  17  +  8 
J17F  26 
E14/R31-27/0  12  +  5 
5RS101  32  +  9 
Before Aftert  Before 
150  300i 
200  200  +-~  ]-+ 
150  250  +q  b+ 
150  150  +~  b+ 
150  150  -~  F 
25  150 
75  150 
75  75  +-F+ 
50  5O  +~  t-+ 
50  1~  +2  t-+ 
75  +-  b+ 
After$ 
i 
-+++ 
-+++ 
-+++ 
-+++ 
-+++ 
-+++ 
-+++ 
-+++ 
-+++ 
~+++ 
-+++ 
75  300  + 
150  500  k+++ 
250  250  + 
100  100 
100  3OO  ++++ 
150  150  Variable 
150  1000  ++++  ++++ 
300  300  ++++  ++++ 
300  300  ++++  ++++ 
I 
75  2oo  ++++++++ 
100  100  ~++++  ++++ 
100  250  ++++  +.+++ 
100  300  ++++  ++++ 
25  300  ++++  ++++ 
200  600  ++++  ++++ 
25  25  Variable 
25  600  --  +++Jr 
200  200  ++++  ++++ 
* No. weeks -- number of weeks which that particular strain could be recovered on culture 
from  nasopharynx  after  inoculation. 
:~ After  --  in this column the highest titre reached following the inoculation is recorded. 
§ NC  -~  not classified. 
]l G  "=  indicates glossy,  avirulent variant. 134  GROUP  A  HEMOLYTIC  STREPTOCOCCI 
impossible to state  whether the animal developed increased resistance  of its 
plasma  clot following inoculation; and  where  they occurred,  the  results  are 
recorded as variable in Table II. 
Table II shows that 4 of the 13 animals exhibited maximal resistance to lysis 
of their plasma clots before their initial inoculations and, therefore, further in- 
creases  in  resistance  to  lysis could  not be  measured.  Three  other  animals 
developed q-q-W-t-  resistance  to lysis of  their plasma  clots following their 
initial  inoculations and  maintained  this  degree of resistance  throughout the 
period of study.  In the 15 cases in which the antifibrinolysin test was nu~ or 
less before inoculation and in which the nasopharyngeal cultures became posi- 
tive,  13  or  86.7  per  cent  developed significant  increases  in  antifibrinolysin 
following inoculation.  On the other hand, in only 1 of 7 instances or 14.3 per 
cent did a significant increase in resistance to lysis occur when the nasopharyn- 
geal cultures were negative following the inoculation.  From these data  it  is 
apparent that in those cases where inoculation was followed by a  persistent 
carrier state for 1 week or longer and by a significant rise in the antistreptolysin 
O titre, the antifibrinolysin test also showed a significant increase in the resist- 
ance of the plasma clot to lysis when it could be measured. 
Table III summarizes all inoculations according to the strain and type em- 
ployed either for primary inoculations or for reinoculations.  Under primary 
inoculations are listed, according to the strain used, all initial inoculations made 
on animals with that particular type.  4  Under reinoculations are listed, accord- 
ing to the strain used, all second and/or third inoculations made on any one 
animal with that particular type.  For example, 8 primary inoculations were 
made with strain 5RS101, type 32, which means that 8 different animals which 
had not previously been inoculated with a type 32 strain received this culture. 
Under the heading "reinoculations" the figures show that these 8 animals re- 
ceived'either strain 5RS101 or C51, both type 32, a second or third time, 4 to 19 
months later. 
Of the 38 primary inoculations, 31 or 81.6 per cent were positive by the cri- 
teria adopted.  Since 4 out of the 7 which gave negative results followed intra- 
nasal instillation of glossy, avirulent strains (T12G or 24RS50G) it is found that 
31 or 91.2 per cent of the 34 primary inoculations made with matt strains re- 
suited in carrier states which persisted for 1 week or longer.  On the other hand, 
when these animals were reinoculated 2 to 27 months later with strains of the 
same type, even though not with the same strain, only 8 or 28.6 per cent of the 
28 reinoculations were positive.  Furthermore, 5 of the 8 positive reinoeulations 
followed negative primary inoculations; 4 of these were made with glossy strains 
4  The inoculations  with strain T12/36/0 listed under primary inoculations  are an exception 
to this statement as both of these animals had previously been inoculated with strain T12 
glossy.  In both instances,  however,  the inoculation  with the T12 glossy  strain failed  to induce 
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and the fifth was made with a matt strain, C630, which failed to induce either 
a  carrier state  or an increase in  the antistreptolysin O  titre.  When these 5 
cases are eliminated, only 3 or 13.1 per cent of the 23 reinoculations were positive 
in the group of animals which had previously been successfully inoculated with 
the same matt type.  That this resistance to reinoculation was type-specific is 
TABLE  III 
Summary of Results of Primary and Reinoculations 
Primary inoculations  Reinoculations 
Strain 
1RS85 
5RSI01 
C51 
llRSS0 
24RS50G§ 
J17F 
T12G§ 
T12/36/O 
E14/R31-27/0 
C63O 
$23/97/1 
1RSC150 
Totals ....... 
Type 
NC* 
32 
32 
26 
26 
26 
12 
12 
12 
14 
14 
17 
Antigenic  ~  ~  ~  Antigen!c 
•  coupes.  composl-  ~  tion 
tion  ~  "~  Strain  r~ 
MIT  ~--~  ~  M  T 
NC [NC  ~  6  I  6  I  0  1RS85  NC  NC  NC 
32  J 32  8  I  8 
32  J 32  2  I  2 
26  O~  5  I  5 
0  0~;  2]0 
26  26  I  2  I  1 
0  12  2  I  0 
12  12  2  I  2 
12  10  2  [  2 
__14 0 .  2 l  1 
14  14  2  [  2 
17  17  ,3  [  2 
'--J'  38  [  31 
I 
SRSI01  32  32  32 
C51  32  ,:]2  32 
11RS50  26  26  0:I: 
J17F  26  26  26 
IIRSS0  26  26  0:~ 
. 
"  '~  ,,"  ~  ,,o 
'm0$.  ~1~$. 
8  1  27  7  6-27 
6  0  --  6  4-19 
2  1  10  1  10 
2  0  --  2  9 
2  1  7  1  7 
2  2  2  0  -- 
T12/36/0  12  12  12  2  2  2  0  -- 
EI4/R31-27/0  12  12  I0  2  0  --  2  3] 
$23/97/1  14  !  14  14  2  1  3  1  3 
28  8  20 
* NC ffi not classified. 
:~ Strains 11RS50 and 24RSSOG  contain a  common agglutinogen which is neither the M  or T  antigen.  I1RS50 
was•btainedfr•mapatientwithacutepharyngitiswhichwasf••••wedbyanattack•frheumatic  fever.  24RSSOG 
was isolated from the same patient 41 months later during convalescence from attack of rheumatic fever.  Strain 
24RS50G recovered its capacity to produce the M antigen which proved to belong to type 26 following serial ani- 
mal passage. 
§ G  indicates  glossy, avirulent  variant. 
shown by the fact that all of the 14 primary inoculations with heterologous matt 
types made on animals already resistant to one or more other types, were posi- 
tive.  (See  Table  II.)  Further,  to  determine  whether  this  resistance  was 
specific with respect to the M  or T  antigen, 5 reinoculations were made with 
strains containing the same type M  but different  type T  antigens.  Thus, 5 
animals  that  had  had  positive  primary inoculations,  2  with  strain  l lRSS0 
(type 26), 2 with T12/36/O (type 12), and one with C630 (type 14), were tested 136  GROUP  A  IIE~OLYTIC  STREPTOCOCCI 
2 to 7 months later; 2 with strain J17F (type 26), 2 with E14/R31-27/O (type 
12), and one with $23/97/1  (type 14) respectively.  Among these 5 animals so 
reinoculated with strains containing the same type M but different T  antigens, 
4  were found to be resistant.  The single  positive reinoculation occurred in 
monkey 36-88 (Table II) with strain J17F (type 26) following a positive primary 
inoculation with strain 11RS50  (type 26).  It may be significant that in this 
case the initial carrier state persisted only 10 days and the animal failed to 
develop an increased antistreptolysin O titre. 
After finding that the monkeys were usually resistant to reimplantation with 
the same type of streptococci to which they had been previously susceptible, it 
became of interest to learn whether they developed type-specific circulating 
antibodies.  The  two tests  selected for this purpose  were  the  agglutination 
reaction and the bacteriostatic test.  It should be recalled that we have already 
demonstrated that 83.8 per cent of the animals successfully  implanted developed 
significant increases  in the  non-type-specific antibody, antistreptolysin O. 
In Table IV are presented the results of agglutination tests made on sera of 
11 monkeys following 20 different inoculations, together with such comparative 
data as success  or failure of intranasal implantations and antistreptolysin O 
responses.  In all 20 instances the homologous type matt strain and heterolo- 
gous type controls were used; while in 15 the homologous type glossy strain 
was also included in the tests to learn whether the agglutinins were directed 
toward the T or M antigen or both.  From this table it appears that 11 of the 
14 successful inoculations were followed by antibody responses to the homolo- 
gous type matt strain as determined by the agglutinin test; but following 5 of 
these  11  inoculations, non-specific agglutinins also appeared  or increased in 
titre if present before the particular inoculation.  In every case, however, the 
fitre developed to the homologous type matt strain was greater than that to 
the heterologous type; and in 6 instances no agglutinins were demonstrable to 
the  heterologous type.  In  contrast it should be  noted that none  of  the  6 
animals unsuccessfully inoculated developed type-specific agglutinins in their 
sera to the homologous matt strain which had been instilled intranasally. 
When the results of the agglutinin tests with homologous type glossy strains 
are considered, it is evident that the titre increased following 7 of 15 inocula- 
tions.  Further analysis of these 7 cases shows that not only did the sera of all 
7 animals have agglutinins to the glossy strain prior to the inoculation, but 
that in 2 animals the agglutinins increased after an unsuccessful inoculation, 
and in one other the antibody increased following inoculation with strain C630 
(type 14)  which did not contain the respective T  antigen.  In view of these 
findings and of the fact that glossy strains are more sensitive to non-specific 
agglutination than are matt strains, it is impossible to attribute the increased 
agglutination  of  the  glossy  strains  to  antibodies  directed  toward  their  T 
antigens.  On the other  hand,  type-specific agglutinins  with respect  to  the ROBERT  F.  WATSON,  SIDNEY  ROTli~ARD,  AND  HOMER  F.  SWIFT  137 
M  antigens could be demonstrated in the sera of most of the animals following 
successful inoculation. 
TABLE  IV 
Results of A gglutination Tests Correlated u~l~ Data on Nasopi~rynge,  al Implan~ion 
aud Antistreptolysin  0  Response 
Monkey  Strain used 
No.  for inoculation 
36-88  IIRSS0 
J17F 
E14/R31-27/0 
36-89  llRS50 
16  J17F 
1RSC150 
19  JI7F 
E14/R31-27/0 
9  24RSSOG§ 
llRSS0 
4-73  T12G 
T12/36/0 
11  24RSSOG 
11RS50 
$23/97/1 
14  C630 
$23/97/1 
15  C630 
17  1RSC150 
18  IRSC150 
Antigenic  Naso-  Anti- 
composition  pharyn-  strep- 
geal  tolysin 
implanta-  0 
tion  increase 
M  T  Before  I  After 
26  0*  -t-  "4-  --  I  1:10~ 
i 
26  26  -I-  0  --  i  I:I0 
12  10  +  -4-  --  ;  -- 
26  0*  -]-  -I-  --  1:80 
26  26  +  +  --  1:40 
17  17  0  0  --  -- 
26  26  0  0  --  -- 
12  10  "4-  "t"  --  1:40 
0  O*  0  0  --  -- 
26  O*  -'}-  -t"  --  1:320 
0  12  0  0  1:160  1:80 
12  12  d-  q-  1:160  1:160 
0  0*  0  0  --  -- 
26  0*  -]-  -[-  --  1:80 
14  14  -4-  -I-  --  -- 
14  0  0  0  --  -- 
14  14  -~  -{-  --  1:I0 
14  0  -4-  -t-  --  1:I0 
17  17  "4-  -4-  --  1:20 
17  17  -]--  ~  --  1:160 
Agglutinin  titers with 
Homologous  Heterologous  Homologous 
type matt  type  type glossy 
Before  After  Before  After 
! 
--  -  I 
I 
--  1:5  --  I  -- 
1:10  1:10  I 
I 
1:5  1:10  --  -- 
--  1:40  --  ]  -- 
i 
--  --  1:20  1:40 
--  1:40  1:20  1:320 
--  1:10  -- 
1:10  1:20  1:20  1:,10 
--  --  1:20  1:40 
__  __  __  ]  -- 
i 
--  --  1:10  1:40 
--  --  1:5  1:40 
1:5  1:40  1:10  1:40 
* Strains 11RS50 and 24RS50G contain a  common agglutinogen which is neither the M or T  antigen.  11RS50 
wasobtainedfromapatientwithacuteptmryngitiswhichwasfolluwedbyanattackof rheumatic fever.  24RSSOG 
was isolated from the same patient 41 months later during convalescence from attack of rheumatic fever.  Strain 
24RSSOG recovered its capacity to produce the M  antigen which proved to belong to type 26 following serial 
animal passage. 
The figure represents the highest serum dilution in which there was definite agglutination.  All figures are 
final dilutions. 
§ G  indicates glossy, aviraleut variant. 
Tests were made for the presence of bacteriostatic antibodies before and after 
13  inoculations  on  12  different animals.  There  was successful  implantation 
of the streptococci for 1 week or more following all of these inoculations  but in 
only 6 instances was there a significant increase in the antistreptolysin O  titres. 138  GROUP  A  HEMOLYTIC  STREPTOCOCCI 
Four of the bacteriostatic tests were done by the direct method; in the remain- 
ing 9 the indirect technique  was used.  Two of  the 4 tests made by the direct 
method were positive;  that is, following these  4 inoculations,  2  animals de- 
veloped definite bacteriostatic antibodies for the strains used for the  inocula- 
tion and not for heterologous type control strains.  By the indirect  method, 
bacteriostatic antibodies were demonstrated following only 2 of 9 inoculations. 
It is noteworthy that in 6 of these instances there was also a failure on the part 
of the animal to develop significant antistreptolysin O in its serum following 
the inoculation.  Although the number of animals (4 of 13 inoculations) which 
developed demonstrable bacteriostatic antibodies is small, it is significant that 
these few developed circulating  antibodies which were definitely type-specific. 
Blood cultures taken at 5 and 24 hour intervals following successful intranasal 
inoculation of 3 animals with strain llRS50 (type 26) and 2 others with strain 
5RS101 (type 32) revealed no growth of group A streptococci.  At the end of 
the period of observation complete autopsies were performed on all but 2 of the 
animals (monkeys 13 and 18), and none showed lesions on either macroscopic 
or microscopic examination suggestive of previous  streptococcal  infections  or 
sequelae.  Also cultures of the deep cervical lymph nodes from 4 of the animals 
were negative for group A streptococci. 
DISCUSSION 
In this study we have demonstrated that most of the Macaca mulat~a inocu- 
lated intranasally with matt strains of group A streptococci  became carriers of 
these  strains  for  several  weeks  to  several  months  following  inoculation. 
Furthermore, when such  a  successful inoculation with a  particular type  of 
group A  streptococcus  occurred,  the animal usually resisted  reimplantation 
with that same  type for several months and sometimes  for a  year or more, 
although implantation with  a  heterologous  type  could  generally  be  easily 
effected.  This resistance  has been  shown  to be  closely correlated  with the 
type-specific M  antigen and not with the T  antigen of the strains employed. 
In addition, a majority of the animals in which implantation was successful 
developed significant increases in their serum antistreptolysin O titers; and in a 
limited number of instances in which the tests were made, type-specific aggluti- 
nins and bacteriostatic antibodies were also demonstrable in the animals' sera 
following successful intranasal implantation.  On the other hand, after intra- 
nasal inoculation with glossy, avirulent strains,  carrier  states could not be  in- 
duced; these  animals,  moreover failed to show antibody responses and were 
susceptible  to implantation with the matt variants of the homologous glossy 
types when tested a few months later. 
From these results it would appear that matt strains of group A streptococci 
are adapted not only for implantation but also for multiplication in the naso- 
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"infected" to  those  animals  in  which  the  streptococci were successfully im- 
planted  and  which  subsequently  developed  circulating  antibody  responses. 
Strictly speaking, we believe the term infection implies not only multiplication 
of the infective agent but also invasion of the host's tissues.  As stated pre- 
viously, none of the animals appeared sick following inoculation; and the white 
blood  cell  count,  erythrocyte sedimentation  rate,  temperature  and  weight 
curves were of no value in  determining whether implantation had occurred. 
Although we have no definite proof that  successful implantation was accom- 
panied by invasion of the animal's tissues, it appears unlikely that the strepto- 
cocci merely colonized on the surface of the monkey's nasopharyngeal mucosa, 
and we, therefore, believe that these animals most likely suffered subclinical 
infections. 
Many workers have demonstrated antibodies to various toxins and to a wide 
variety of bacteria and viruses in human beings as well as in lower animals 
with no history or obvious signs of previous infections or of contacts with the 
agents.  Needless to  say,  much discussion  has  arisen  as  to the  stimulus  re- 
sponsible for the production of these antibodies; whether the antibodies are so 
called natural antibodies or whether they have developed in response to contact 
or subclinical infection with the agent toward which they are directed or toward 
other antigens containing similar haptogenic chemical groups.  Although the 
data presented in this communication do not contribute directly toward the 
solution of this question, they do indicate that an anlmal may develop specific 
antibodies to bacterial antigens without manifesting any demonstrable signs or 
symptoms Of infection. 
In this connection it is of interest that Kuttner (34) found, in a series of 38 
children who suffered dear-cut  rheumatic recurrences, that 19 or 50 per cent 
had either no signs  or symptoms of the preceding streptococcal infection or 
the signs and symptoms were so slight that they were detected only because the 
patients were in an institution where the temperature was checked three times a 
day and throat cultures were taken as routine every week, or more often when 
indicated.  It is significant, however, that 15 or 79 per cent of these 19 children 
developed a  rise in their antistreptolysin O titers following the  appearance of 
streptococci in their throats.  Our own observations (35) on a  group of rheu- 
matic  subjects  are  in  accord with  these  findings.  More recently the  U.  S. 
Army Commission on Acute Respiratory Diseases  (36)  found significant in- 
creases in the antistreptolysin O titres or the antifibrinolysin test in nearly half 
of the "healthy" carriers of group A type 5 streptococci following an explosive 
epidemic of septic sore  throats  in  troops; and  expressed the  opinion that  a 
proportion of these carriers were subclinical cases.  It is aho of interest that 
only those carriers who harbored the streptococci for 10 days or more exhibited 
antibody responses. 
The results of the experiments with monkeys are in agreement with informa- 140  GROUP  A  HEMOLYTIC  STREPTOCOCCI 
tion previously gained regarding immunity to group A streptococcal infections 
in rodents; that is, immunity is type-specific with respect to the M  content of 
group A streptococci in that this immunity or protection is due to the antibody 
directed toward the type-specific M  and not toward the T  antigen.  Also the 
results are in accord with the known information regarding immunity to group 
A streptococcal  infections in  man.  As  previously mentioned,  not  a  single 
case has been reported in which it has been shown that a patient suffered two 
separate respiratory tract infections with the same type of streptococcus.  It 
is well established, on the other hand, that many of the late purulent compli- 
cations and almost invariably the relapses and recurrent sore throats occurring 
in scarlet fever patients are due to types of streptococci other than those which 
caused the original scarlatinal infection.  Although autogenous reinfections of 
other parts of the body do occasionally occur with the same type of strepto- 
coccus which had previously caused a nasopharyngeal infection, it seems likely 
that in these cases the site of infection was particularly susceptible to invasion, 
as in the case of the parturient uterus, or that the dose of the infecting micro- 
organisms was overwhelming, or that both  conditions prevailed.  It is  also 
possible, even probable, that certain individuals are poor antibody producers 
and that certain types of streptococci are poor antigens in so far as the type- 
specific M antigen is concerned. 
We have recently been able to show with the bacteriostatic test that following 
nasopharyngeal infections with group A  streptococci the majority of human 
beings develop circulating type-specific antibodies, which, in certain instances, 
have  been  demonstrable for  periods as long as  12  to  24  months following 
the infections (37).  These observations, correlated with the present data from 
monkey inoculations and with previous studies on rodents,  make it appear 
likely that man usually develops some degree of type-specific resistance follow- 
ing group A streptococcal infections.  One cannot state at present the duration 
of such a type-specific immunity  in man.  Doubtless the probability of a second 
infection with a given type will depend on several factors: the size of the rein- 
fecting dose; the site and condition of the reinfected tissues; and the degree of 
immunity  remaining from the previous infection. 
Even though these factors cannot be accurately appraised, it is now evident 
that' patients with group A  streptococcal infections, such as scarlet fever or 
tonsillitis, even though exhibiting similar clinical signs and symptoms, should 
be considered as potential sources of danger, one to the other, unless it can be 
established that contiguous patients have the same type of streptococci causing 
their: respective infection.  In o[her words, from the standpoint of isolation, 
patients infected with different types of group  A  streptococci should be  as 
carefully  isolated  as  though  they  were  suffering  from  different  infectious 
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SU~r~y AND CONCLUSIONS 
1.  Nasopharyngeal carrier states of several weeks to several months duration 
were induced in the Macaca mula#a by the intranasal inoculation with matt 
strains of group A streptococci. 
2.  Following such a successful inoculation with a particular type of group A 
streptococcus,  the animal was  usually resistant to  reimplantation with that 
same type for several months to a year or more, although reimplantation with 
a heterologous type could generally be easily effected. 
3.  This resistance was shown to be  closely correlated with the antibodies 
directed toward the type-specific M  antigen, not toward the T  antigen of the 
strains employed. 
4.  A majority (83.8 per cent) of the animals in which intranasal inoculation 
was followed by successful implantation developed significant increases in the 
antistreptolysin O  titres of their sera; and in a  limited number of instances, 
type-specific agglutinins and  bacteriostatic antibodies  were  demonstrable in 
the animals' sera following successful implantation. 
5.  Nasopharyngeal  carrier  states  could  not  be  induced  with  the  glossy, 
avirulent variants of group A streptococci; these animals, moreover, failed to 
show antibody responses and were susceptible to implantation with the matt 
variants of the homologous glossy strains. 
6.  The findings are in accord with the known facts regarding immunity to 
group A streptococci gained through experiments on rodents; and the possible 
relationship of these observations to the problem of type-specific immunity ill 
human beings is discussed. 
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